AI-accelerated discovery across oncology, immunology and metabolic diseases — from signal to candidate at unprecedented speed using MedGraphTM
0
Total Programs
0
Disease Areas
INDICATION
TARGET
TYPE
STAGE
Triple Negative Breast Cancer
TNBC
Undisclosed*
RPE/NCE
PRE-DISCOVERYDISCOVERYPRECLINICALCLINICAL
⬡ Synthetic lethality via DNA damage response modulation
This program targets DNA repair vulnerabilities in triple negative breast cancer, particularly in BRCA wild-type settings, using AI-driven generative design and physics-based validation to identify novel scaffolds, with ongoing experimental evaluation in collaboration with ACTREC-TMC to generate differentiated candidates capable of sensitizing tumors to DNA damage and combination therapies.
Acute Lymphoblastic Leukemia
ALL
Undisclosed
Enzyme
PRE-DISCOVERYDISCOVERYPRECLINICALCLINICAL
⬡ Systemic depletion of extracellular asparagine via engineered enzyme variants
This program focuses on engineering next-generation asparaginase variants with improved stability and reduced immunogenicity using AI-guided protein design, with prioritized candidates undergoing early experimental validation in collaboration with ACTREC-TMC and positioned for expansion into solid tumor applications going ahead.
Neurodegeneration & Inflammatory Disorders
Parkinson’s, Alzheimer’s, ALS
Undisclosed*
NCE
PRE-DISCOVERYDISCOVERYPRECLINICALCLINICAL
⬡ Modulation of protein aggregation and neuroinflammation pathways
This program targets key pathological drivers of neurodegenerative diseases including Alzheimer’s, Parkinson’s, and ALS through AI-driven target discovery and generative chemistry workflows, with shortlisted molecules progressing toward synthesis and validation to enable innovative modulators for complex disease biology.
Pan-Oncology DDR Program
Breast, Prostate, Ovarian Cancer
Undisclosed*
NCE
PRE-DISCOVERYDISCOVERYPRECLINICALCLINICAL
⬡ Targeting conserved DNA damage response regulators
This program leverages knowledge graph-driven target discovery and generative AI to identify novel, druggable vulnerabilities across multiple cancer types, generating diverse molecular libraries and enabling scalable expansion of Medvolt’s oncology pipeline.
Chordoma
Skull Base & Sacral
Undisclosed*
NCE
PRE-DISCOVERYDISCOVERYPRECLINICALCLINICAL
⬡ Inhibition of chordoma growth and survival pathways
An AI-driven small-molecule program for chordoma, a rare bone cancer of the skull base and spine. Using generative design, structure-guided screening, and simulation workflows, promising hits have been identified and advanced through molecular dynamics validation, with further research ongoing.
NCE
New Chemical Entity
Novel small molecules designed or identified through Medvolt's AI-driven drug discovery platform.
RPE
Re-purposed Entity
Existing compounds repositioned for new indications using ML-identified mechanisms of action.
Enzyme Therapeutics
Precision Biologic Medicines
AI-engineered enzyme therapeutics targeting key metabolic and biochemical pathways.
STRATEGIC PARTNERSHIPS
Interested in Partnering?
We're selectively engaging strategic partners and investors. Reach out to access our full pipeline brief and target disclosures under CDA.
Pipeline information is current as of Q2 2026 and subject to change without notice. * Full target disclosure available upon execution of a Confidentiality Disclosure Agreement (CDA).
Why Medvolt
Accelerate Discovery
Medvolt's AI-powered platform cuts pre-clinical discovery time by 3x, reduces costs by 15x and lowers failure risk by 25%. Enhance your R&D efficiency with our in silico tools.
High-Throughput Data
Enrich your research with Medvolt's proprietary, gold-standard, high-throughput proprietary datasets. Our AI and NLP solutions deliver speed, precision and scalability.
Expert Collaboration
Our experienced, tech-driven team collaborates globally with leading pharma and biotech companies, ensuring impactful, scalable solutions.
